BIOMAT Database Logo BIOMAT Database Logo

Plasminogen activator levels are influenced by location and varicosity in greater saphenous vein. 1996

P K Shireman, and W J McCarthy, and W H Pearce, and V P Shively, and M Cipollone, and H C Kwaan, and J S Yao
Department of Surgery, Northwestern University School of Medicine, Chicago, IL 60611, USA.

OBJECTIVE The plasminogen system, which includes tissue type plasminogen activator (tPA), urokinase type plasminogen activator (uPA), and their main inhibitor, plasminogen activator inhibitor type 1 (PAI-1), plays a major role in both fibrinolysis and tissue remodeling. This study compares the levels of tPA, uPA, and PAI-1 at the groin and ankle in normal and varicose greater saphenous vein (GSV). METHODS GSV was collected from patients undergoing varicose vein (VV) removal and from normal vein (NV) from arterial bypass procedures. Portions of the GSV at the groin and the ankle were minced and placed in serum-free media for 48 hours. Assays of the supernatants were obtained for tPA, uPA, and PAI-1 protein by enzyme-linked immunosorbent assay. Cyclohexamide and actinomycin D were also added to the media of the VV tissue explant supernatants to inhibit protein and RNA synthesis, respectively. RESULTS Levels of tPA were significantly higher at the groin (11 +/- 2) than the ankle (5 +/- 1) in the VV (p < 0.005), and this trend was also seen in the NV (groin 10 +/- 2 and ankle 7 +/- 3). Levels of uPA were significantly higher in the groin VV (14 +/- 4.3) than in NV (3.0 +/- 0.8, p < 0.05). This difference, although not statistically significant, applied to the ankle as well (VV 14.5 +/- 6.3 and NV 5.3 +/- 2.7). No significant difference was seen between NV and VV for PAI-1 (NV, groin 155 +/- 73 and ankle 113 +/- 53, VV, groin 161 +/- 20 and ankle 142 +/- 38) or tPA. Inhibitor studies revealed no significant difference among control, cyclohexamide, and actinomycin D supernatants for tPA, suggesting release of protein rather than active synthesis. In contrast, inhibitor supernatants were significantly lower for uPA and PAI-1 than control supernatants (p < 0.05), suggesting that uPA and PAI-1 were actively synthesized. CONCLUSIONS In the tissue explant supernatant model uPA and PAI-1 are actively synthesized, but tPA is not. Levels of PAI-1 were comparable in all four groups. Levels of uPA in the varicose GSV were higher than in NV, suggesting a role for uPA in the pathologic makeup of VV. Levels of tPA were higher at the groin versus the ankle position, potentially explaining the previously described increased fibrinolytic activity seen at the groin.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D010960 Plasminogen Activators A heterogeneous group of proteolytic enzymes that convert PLASMINOGEN to FIBRINOLYSIN. They are concentrated in the lysosomes of most cells and in the vascular endothelium, particularly in the vessels of the microcirculation. Extrinsic Plasminogen Activators,Plasminogen Activator,Uterine-Tissue Plasminogen Activator,Uterine Tissue Plasminogen Activator
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006119 Groin The external junctural region between the lower part of the abdomen and the thigh. Groins
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000842 Ankle The region of the lower limb between the FOOT and the LEG. Tarsus,Regio tarsalis,Ankles
D012501 Saphenous Vein The vein which drains the foot and leg. Saphenous Veins,Vein, Saphenous,Veins, Saphenous
D014568 Urokinase-Type Plasminogen Activator A proteolytic enzyme that converts PLASMINOGEN to FIBRINOLYSIN where the preferential cleavage is between ARGININE and VALINE. It was isolated originally from human URINE, but is found in most tissues of most VERTEBRATES. Plasminogen Activator, Urokinase-Type,U-Plasminogen Activator,Urinary Plasminogen Activator,Urokinase,Abbokinase,Kidney Plasminogen Activator,Renokinase,Single-Chain Urokinase-Type Plasminogen Activator,U-PA,Single Chain Urokinase Type Plasminogen Activator,U Plasminogen Activator,Urokinase Type Plasminogen Activator

Related Publications

P K Shireman, and W J McCarthy, and W H Pearce, and V P Shively, and M Cipollone, and H C Kwaan, and J S Yao
Greater saphenous vein location in a pediatric population.
December 2012, Journal of pediatric nursing,
P K Shireman, and W J McCarthy, and W H Pearce, and V P Shively, and M Cipollone, and H C Kwaan, and J S Yao
Plasminogen activator and plasminogen activator inhibitor gene expression in human saphenous vein organ culture.
April 2001, Experimental and molecular pathology,
P K Shireman, and W J McCarthy, and W H Pearce, and V P Shively, and M Cipollone, and H C Kwaan, and J S Yao
[Essential varicosity of the lesser saphenous vein].
January 1973, Phlebologie,
P K Shireman, and W J McCarthy, and W H Pearce, and V P Shively, and M Cipollone, and H C Kwaan, and J S Yao
The levels of soluble urokinase plasminogen activator receptor (suPAR) in saliva are influenced by acute stress.
October 2021, Biological psychology,
P K Shireman, and W J McCarthy, and W H Pearce, and V P Shively, and M Cipollone, and H C Kwaan, and J S Yao
[Problems posed by varicosity of the lesser saphenous vein. Introduction].
January 1973, Phlebologie,
P K Shireman, and W J McCarthy, and W H Pearce, and V P Shively, and M Cipollone, and H C Kwaan, and J S Yao
Varicosity of the external and pseudo-varicosity of the short (external) saphenous vein.
March 1959, The British journal of surgery,
P K Shireman, and W J McCarthy, and W H Pearce, and V P Shively, and M Cipollone, and H C Kwaan, and J S Yao
Systemic and local saphenous vein graft thrombolysis using a tissue plasminogen activator.
March 1990, Catheterization and cardiovascular diagnosis,
P K Shireman, and W J McCarthy, and W H Pearce, and V P Shively, and M Cipollone, and H C Kwaan, and J S Yao
Thrombolysis with recombinant tissue plasminogen activator in late saphenous vein graft thrombosis.
April 1990, American heart journal,
P K Shireman, and W J McCarthy, and W H Pearce, and V P Shively, and M Cipollone, and H C Kwaan, and J S Yao
Invasive therapeutic options in truncal varicosity of the great saphenous vein.
August 2006, VASA. Zeitschrift fur Gefasskrankheiten,
P K Shireman, and W J McCarthy, and W H Pearce, and V P Shively, and M Cipollone, and H C Kwaan, and J S Yao
Bypass in the absence of ipsilateral greater saphenous vein: safety and superiority of the contralateral greater saphenous vein.
June 2002, Journal of vascular surgery,
Copied contents to your clipboard!